Therapeutic targeting of myeloid-derived suppressor cells

Curr Opin Pharmacol. 2009 Aug;9(4):470-81. doi: 10.1016/j.coph.2009.06.014. Epub 2009 Jul 16.


Myeloid-derived suppressor cells (MDSCs) represent a subset of myeloid cells that expand under pathological conditions, such as cancer development, acute and chronic infections, trauma, bone marrow transplantations, and some autoimmune diseases. MDSCs mediate a negative regulation of the immune response by affecting different T lymphocyte subsets. Potential mechanisms, which underlie this inhibitory activity range from those requiring direct cell-to-cell contact with others, more indirect, and mediated by the modification of the microenvironment. Pharmacological inhibition of MDSC suppressive pathways is a promising strategy to overcome disease-induced immune defects, which might be a key step in enhancing the effectiveness of immune-based therapies.

Publication types

  • Review

MeSH terms

  • Animals
  • Autoimmune Diseases / drug therapy
  • Autoimmune Diseases / metabolism
  • Autoimmune Diseases / pathology
  • Drug Delivery Systems* / methods
  • Humans
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / immunology
  • Immunologic Factors / pharmacology
  • Immunologic Factors / physiology*
  • Immunologic Factors / therapeutic use
  • Myeloid Cells / drug effects
  • Myeloid Cells / immunology*
  • Suppressor Factors, Immunologic / physiology*


  • Immunologic Factors
  • Suppressor Factors, Immunologic